Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A new draft guideline published today aims to address this widespread variation by recommending a standardised approach to rehabilitation across five major neurological conditions, including brain and ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Suggested remit: To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for previously treated severe nasal polyps. As you will be aware, the Department for ...

11 February 2025 - 25 February 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators For further information on how we select topics for ...

Further information The NICE-Wide Prioritisation Board met November 2024. The Prioritisation Board considered the technology at length. It recognised the difference in commissioning of narcolepsy ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...